Given its role in inhibiting nerve regeneration, Nogo-A has significant clinical implications. Therapeutic strategies are being explored to neutralize Nogo-A activity to promote neuroregeneration following CNS injuries such as spinal cord injuries and stroke. Antibodies and small molecules that can block Nogo-A or its receptors are being investigated for their potential to enhance neural repair and functional recovery.
